Compare Affirm Holdings Inc (AFRM) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Affirm Holdings Inc vs Eli Lilly And Co — how do they compare? Affirm Holdings Inc trades at $73.88 (market cap $25.69B), while Eli Lilly And Co trades at $1,217.59 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 42× Affirm Holdings Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Affirm Holdings Inc pays none. Which is the better fit depends on your goals.
| AFRM | LLY | |
|---|---|---|
Market Cap | $25.69B | $1.08T |
Sector | Financials | Health |
52-Week High | $92.18 | $1.24K |
52-Week Low | $42.53 | $639.43 |
Enterprise Value | $32.30B | $1.13T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $75.54, up 0.39% today, with a bullish technical signal and consistent earnings beats. Revenue grew to $3.22B in 2025, turning profitable with $52M net income. The stock faces resistance near $76-$78, while analyst consensus targets $96.40, implying 28% upside. Recent news highlights strong growth prospects and institutional interest.
Outlook is positive given accelerating revenue growth, expanding margins, and dominant buy-side analyst support. Key risks include high valuation multiples (P/E 69.7) and sensitivity to interest rate changes, but robust cash flow generation and market share gains support long-term upside.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
